Chester County News and Community Website
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) will present preclinical data on two cancer drug candidates at the American Association for Cancer Research Annual Meeting 2026 in San …
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026 Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported financial results for the year ended December 31, 2025, and said it expects pivotal Phase 3 data for its lung …
ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib Read More NEWTOWN SQUARE, PA — ArriVent BioPharma has dosed the first patient in a global Phase 3 study that could reshape first-line treatment for a small but hard-to-treat group of lung …
Firmonertinib Trial Aims to Crack a Long-Standing Lung Cancer Treatment Gap Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported third-quarter financial results and outlined major clinical milestones that position the company for a pivotal two-year stretch focused on advancing …
ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has appointed Brent S. Rice as Chief Commercial Officer, bringing more than 25 years of commercial leadership experience in the biotechnology …
ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer Read More NEWTOWN SQUARE, PA – ArriVent BioPharma, Inc. (Nasdaq: AVBP) presented final proof-of-concept results from its global Phase 1b FURTHER trial of firmonertinib, an oral targeted therapy for patients with non-small …
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported a wider second-quarter loss as the company pressed forward with late-stage development of its lead cancer drug, firmonertinib, and advanced …
ArriVent BioPharma Posts Q2 Loss as Cancer Drug Pipeline Advances Toward Key Milestones Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced it expects topline data in early 2026 from its global Phase 3 FURVENT trial evaluating firmonertinib as a first-line treatment …
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has shared encouraging interim results from its Phase 1b FURTHER trial, which investigates firmonertinib as a first-line monotherapy for non-small cell …
ArriVent BioPharma Reports Promising Results from Phase 1b Trial for Firmonertinib in NSCLC Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced that it will host a virtual investor event on June 23, 2025, at 8:00 am ET. The event will focus …
ArriVent BioPharma to Host Investor Event on Groundbreaking Firmonertinib Program for EGFR Mutant NSCLC Read More